Solid Biosciences Inc
SLDB5.900USD
-0.080-1.34%
收盤 12/23, 16:00（美東）報價延遲15分鐘
459.51M總市值
虧損本益比TTM
關於 Solid Biosciences Inc 公司
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc簡介
公司代碼SLDB
公司名稱Solid Biosciences Inc
上市日期Jan 26, 2018
CEOCumbo (Alexander)
員工數量100
證券類型Ordinary Share
年結日Jan 26
公司地址500 Rutherford Avenue
城市CHARLESTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02129
電話16173374680
網址https://www.solidbio.com/
公司代碼SLDB
上市日期Jan 26, 2018
CEOCumbo (Alexander)
Solid Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
129.65K
-2.47%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
126.69K
+3.74%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
78.52K
+29.32%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
32.91K
+32.75%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
26.66K
+38.27%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
17.77K
+34.30%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
129.65K
-2.47%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
126.69K
+3.74%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
78.52K
+29.32%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
32.91K
+32.75%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
26.66K
+38.27%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
收入明細
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
其他
52.47%
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
其他
52.47%
股東類型
持股股東
佔比
Investment Advisor
38.12%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.55%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
0.61%
Bank and Trust
0.13%
Pension Fund
0.07%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
11.91M
15.29%
--
--
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.16%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Jun 30, 2025
RA Capital Management, LP
5.81M
7.46%
+100.00
+0.00%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
4.37M
5.61%
+2.45M
+127.89%
Jun 30, 2025
Adage Capital Management, L.P.
6.73M
8.64%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.37M
4.32%
+905.10K
+36.79%
Jun 30, 2025
Vestal Point Capital, LP
1.50M
1.93%
-248.56K
-14.17%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.18M
4.08%
-339.49K
-9.65%
Jun 30, 2025
Citadel Advisors LLC
2.52M
3.24%
+637.41K
+33.80%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
iShares Neuroscience and Healthcare ETF
佔比0.52%
iShares Micro-Cap ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
公告日期
類型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
常見問題
Solid Biosciences Inc的前五大股東是誰？
Solid Biosciences Inc的前五大股東如下：
Perceptive Advisors LLC持有股份：11.91M佔總股份比例：15.29%。
Bain Capital Life Sciences Investors, LLC持有股份：7.91M佔總股份比例：10.16%。
Invus Public Equities Advisors, LLC持有股份：7.42M佔總股份比例：9.52%。
RA Capital Management, LP持有股份：5.81M佔總股份比例：7.46%。
BlackRock Institutional Trust Company, N.A.持有股份：4.37M佔總股份比例：5.61%。
Perceptive Advisors LLC持有股份：11.91M佔總股份比例：15.29%。
Bain Capital Life Sciences Investors, LLC持有股份：7.91M佔總股份比例：10.16%。
Invus Public Equities Advisors, LLC持有股份：7.42M佔總股份比例：9.52%。
RA Capital Management, LP持有股份：5.81M佔總股份比例：7.46%。
BlackRock Institutional Trust Company, N.A.持有股份：4.37M佔總股份比例：5.61%。
Solid Biosciences Inc的前三大股東類型是什麼？
Solid Biosciences Inc 的前三大股東類型分別是：
Perceptive Advisors LLC
Bain Capital Life Sciences Investors, LLC
Invus Public Equities Advisors, LLC
Perceptive Advisors LLC
Bain Capital Life Sciences Investors, LLC
Invus Public Equities Advisors, LLC
有多少機構持有Solid Biosciences Inc(SLDB)的股份？
截至2025Q3，共有245家機構持有Solid Biosciences Inc的股份，合計持有的股份價值約為82.26M，占公司總股份的105.58% 。與2025Q2相比，機構持股有所增加，增幅為0.99%。
哪個業務部門對Solid Biosciences Inc的收入貢獻最大？
在FY2023，--業務部門對Solid Biosciences Inc的收入貢獻最大，創收--，占總收入的--% 。
